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2.1 Introduction
In these days when declining birth rates and
graying are reported to be ongoing in Japan, many
people desire not only to live a long life but also to
spend their old days in good health. In this
increasingly graying society, we might be obliged
to not only receive care but also administer care to
someone. According to the report on the "Basic
Investigation of National Life" in 1998, published
by the Ministry of Health, Labor and Welfare, about
81% (one million people) of the roughly 1.24
million Japanese citizens requiring care at home is
represented by people aged 65 years or older.
Furthermore, about 53% of the people who are
administering care to those aged 65 years or older
requiring at-home care is constituted by the
elderly aged 60 years or more.
Under these circumstances, dementia has become
a grave concern to many people. According to the
"Report on Special Investigation of the Actual
Conditions and Health of the Elderly" in 1997,
published by the Tokyo metropolitan government,
about 4% of the elderly aged 65 years or more
living at home have developed dementia.
Furthermore, according to the report on the
"Projected future population of Japan" in 1997,
published by the National Institute of Population
and Social Security Research, Ministry of Health,
Labor and Welfare, the number of elderly people
with dementia in Japan reached 1.56 million in
2000, which is expected to increase sharply to
2.26 million in 2010, and further to 2.92 million in
2020.
Against this backdrop, in the Phase Two
Technology Master Plan (adopted at the Cabinet
meeting held in March 2001), elucidation of the
mechanism of brain aging and suppression of
nervous system diseases were selected as strategic
challenges to be addressed with high priority in
order to tackle national and social problems.
In the 7th Technology Foresight, whose results
were published by the National Institute of
Science and Technology Policy, survey of the
current state of research on Alzheimer's disease, a
common type of dementia, was conducted and the
outlook for the challenges to be addressed
through research on the disease was given. The
challenges mentioned and year when each of
those challenges is expected to be accomplished
is as follows:
• "Elucidation of the mechanism of development
of Alzheimer's disease".......... 2014
• "Inhibition of the progression of Alzheimer's
disease".......... 2017
• "Development of therapy that completely
cures Alzheimer's disease".......... 2020
Under circumstances where the Japanese
government has taken various measures to cope
with problems arising in this graying Japanese
society such as the provision of nursing care
services and establishment of facilities for nursing
care, to what extent has research targeting the
suppression of Alzheimer's disease been pursued?
In order to find the answer to this question, we
invited Professor Takeshi Iwatsubo, Graduate
School of Pharmaceutical Sciences, Faculty of
Pharmaceutical Sciences, University of Tokyo to
have him deliver a lecture about recent trends in
research on dementia, especially on Alzheimer's
disease, at the Institute of Policy for Science and
Technology on December 11, 2001, and wrote this
article as the summary of the contents of his
lecture while incorporating the data from our
study.
This report discusses the "General description of
dementia (section 2.2), "Characteristics of
Alzheimer's disease" (section 2.3), "Current state
of research on the mechanism of Alzheimer's
disease development" (section 2.4), "Current state
of development work on pharmaceutical products
for Alzheimer's disease" (section 2.5), and
"Strategies for promoting research on Alzheimer's
disease in Japan" (section 2.6), and, in the last
section, gives a summary of "Challenges to be
addressed through research on Alzheimer's
disease" (section 2.7).
2.2 General description of
dementia
Dementia is a disorder of memory and intelligence
(judgement, cognitive function, etc.) in adults.
With aging, people become more forgetful but can
live a normal life as a member of society if they
still have normal judgement, etc. On the other
hand, patients with dementia have not only
memory disturbance but also intelligence disorder,
so they cannot live a normal life as a member of
society. In most cases, dementia occurs when
nerve cells in a certain region of the brain are
damaged from some cause and are lost.
Dementia can be classified into various groups
including senile dementia, dementia caused by
abnormality of proteins, etc. (e.g., Alzheimer's
disease), that following the onset of
cerebrovascular disease (cerebrovascular
dementia), that associated with the displacement
of a part of the brain (displacement of
neurovascular structures), that caused by brain
tumors, etc., as well as due to infectious diseases
including prion disease, etc.
The two most common types of dementia are
Alzheimer's disease and cerebrovascular dementia.
2.3 Characteristics of
Alzheimer's disease
Dementia is diagnosed by step-by-step elimination
of other diagnoses, which are conceivable in light
of the patients' clinical history, as well as findings
from physical examination or from diagnostic
imaging, etc. However, in the last ten some odd
years, studies on Alzheimer's disease have greatly
advanced and produced a variety of scientific
evidences.
The first report on a patient with Alzheimer's
disease (AD) was made by Alois Alzheimer in 1906.
The patient died at the age of 51. During autopsy,
marked cerebral atrophy (shrinkage of the brain)
was observed, and many granular structures and
degenerated nerve cells with thick tangled fibrils
were seen mainly in the cerebral cortex.
Principal symptoms of Alzheimer's disease include
progressive and irreversible dementia, particularly
memory disorder, orientation disturbance
(impairment in the ability to recognize one's
surroundings and their temporal and spatial
relationship to oneself), as well as impaired
judgement. In the brain of patients with
Alzheimer's disease, characteristic histo-
pathological changes are noted such as marked
cerebral atrophy, as well as deposition of senile
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Figure 1: Senile plaques and neurofibrillary degeneration
Brain tissue sample taken from a patient with Alzheimer's disease was stained using a
special staining technique.
Source: Materials provided by Professor Takeshi Iwatsubo
plaques (Figure 1) and tangled bundles of fibers
called neurofibrillary tangles (Figure 1) due to the
accumulation of abnormal proteins. Other brain
changes in people with Alzheimer's disease
include death and loss of nerve cells (neuronal
loss) in areas of the brain (cerebral neocortex and
hippocampus) that are vital to higher-order
cognitive functions such as memory and learning.
The senile plaque is histopathological change
observed only in patients with Alzheimer's disease
or Down's syndrome, or the elderly, while
neurofibrillary degeneration is associated with
various diseases. During the course of Alzheimer's
disease, senile plaques appear at the earlier stage,
and neurofibrillary degeneration takes place at the
advanced stage of the disease.
After the first report by Dr.Alois Alzheimer, studies
on these structures started. Electron microscopic
studies and subsequent immunohistochemical
studies have provided clues for clarifying the
causes of the accumulation of abnormal proteins.
Currently, the mechanism of the development of
Alzheimer's disease is well on the way to
becoming elucidated by studies also adopting
molecular biological techniques.
A certain type of Alzheimer's disease (familial
Alzheimer's disease) has been found to occur in
specific families. Molecular generic studies in
such families have yielded many significant
findings. In around the early 1990s, patients with
Alzheimer's disease were found to have mutation
on genes from a protein called amyloid beta. In
parallel with studies on such genes, research on
causative agents of neurofibrillary degeneration
(see section 2.4.3) had been pursued. Then,
researchers trying to elucidate the causative
agents of Alzheimer's disease had competed
fiercely to identify the major constituents of the
two histopathologically abnormal structures, i.e.,
senile plaques and neurofibrillary tangles. At
present, based on the results of many studies, the
theory that accumulation of amyloid beta is deeply
involved in the development of Alzheimer's
disease has gained strong support. On the other
hand, it has been reported that the major
constituent of neurofibrillary tangles seems to play
a significant role in inducing nerve cell death.
2.4 Current state of
research on the mechanism
of Alzheimer's disease
development
2.4.1  Major molecules involved in
the deposition of senile plaques
Deposition of senile plaques, one of the
characteristic histopathological findings seen in
the brain of Alzheimer's disease patients, results
from the extracellular accumulation of amyloid
beta protein (Aβ), which is a protein rarely seen in
normal brains. Generally speaking, amyloid refers
to the bundle of protein fibrils. Amyloid is barely
soluble and is apt to clump (aggregation) and
accumulate. The letter "β" in the name of amyloid
β, which appears in the brains of Alzheimer's
disease patients, is derived from the fact that the
protein has a characteristic conformational
structure called β sheet. This β sheet structure
contributes to the protein's predisposition to
aggregate.
Aβ is processed from the amyloid β precursor
protein (APP) (Figure 2). The role of APP, which is
expressed in all organs and tissues of the body, has
not been fully elucidated as of yet.
In the processing of Aβ, two enzymes, i.e., β and γ
secretases, are involved; β secretase works first,
and then γ secretase.
Aβ can be classified into two groups including
Aβ40 and Aβ42 according to the number of
constituent amino acids. Aβ42 has a stronger
tendency to aggregate one another as compared
with Aβ40. In addition,Aβ42 is closely involved in
the formation and distribution of senile plaques.
2.4.2  Molecules involved in the degradation of
Aß
In the human body,Aβ is steadily generated under
normal conditions. However, under normal
metabolic conditions, Aβ is thought to be rapidly
degraded following its generation before it
aggregates or accumulates. In studies on non-
familial, sporadic Alzheimer's disease, it has been
reported that decreased degradation of Aβ may
lead to its accumulation.
While the mechanism of the degradation of Aβ has
not been clarified, Japanese researchers recently
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reported new findings with regard to the
mechanism. Nishimichi et al. at the Brain Science
Institute, the Institute of Physical and Chemical
Research has published an article entitled
"Identification of the Metabolic Pathway involved
in the Decrease of Aβ42 Predominantly Expressed
in the Brain Tissue" in the journal Nature Medicine
in 2000, which suggests for the first time that an
enzyme called "neprilysin" is involved in the
degradation of Aβ. Subsequently, in 2001,
Nishimichi et al. published an article entitled
"Control of Cerebral Metabolism of Aβ by
neprilysin" in the journal Science. In the study
reported in this article, he demonstrated that Aβ
increases in the brain of neprilysin-knockout mice
(mice whose genes for neprilysin are knocked out
by genetic engineering) , showing that neprilysin
is involved in the degradation of Aβ.
2.4.3  Mechanism of the development of
neurofibrillary degeneration
In addition to senile plaques, neurofibrillary
tangles are characteristically seen in patients with
Alzheimer's disease. As is the case with senile
plaques, neurofibrillary degeneration is caused by
the accumulation of abnormal proteins.
Neurofibrillary tangles are abnormal fibrous
structures and are composed mainly of paired
helical filaments (PHF) consisting of two helical
proteins. In contrast to Aβ which forms senile
plaques extracellularly, PHF is accumulated in
nerve cells. Figure 3 shows the process of PHF
generation. In nerve cells, there is an organelle
called microtubule, whose major functions are to
maintain cytoskeleton and transport substances
intracellularly. Tau protein is a substance whose
function is to place microtubules in a specific
direction and at regular spatial intervals to
stabilize them. When the tau protein is hyper-
phosphorylated for some reason or another, it will
leave the microtubule, and hyperphosphorylated
tau proteins are believed to aggregate to form PHF.
Moreover, it is speculated that PHFs also aggregate
one another and accumulate in nerve cells, leading
to neurofibrillary degeneration.
2.4.4  Challenges to be addressed through
future research
With regard to the mechanism of the development
of Alzheimer's disease, observational findings
strongly support the hypothesis that onset of the
disease is first triggered by the accumulation of
Aβ, which is followed by the accumulation of
hyperphosphorylated tau proteins, resulting in
nerve cell death. Currently, investigation on the
pathway from the accumulation of Aβ to the
accumulation of hyperphosphorylated tau
proteins is being actively conducted. In a recent
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Figure 2: Processing from APP into Aß
study using genetically engineered mice, it was
reported that a certain relationship was actually
noted between Aβ and hyperphosphorylated tau
protein.
In addition, research on the mechanism of
excessive phosphorylation of tau protein has also
been performed. Such research will evolve into
that aiming to find the mechanism through which
development of Alzheimer's disease can be
inhibited.
Furthermore, many studies on the ultimate
mechanism of nerve cell death are also in
progress. There are some diseases other than
Alzheimer's disease, which are caused by
excessive phosphorylation. herefore, it is
expected that elucidation of the mechanism of the
excessive phosphorylation will lead to advances in
studies not only on Alzheimer's disease but also on
some other diseases.
Concerning familial Alzheimer's disease, results of
studies have indicated that there still exist
Alzheimer's disease susceptibility genes, which
have not been found so far, and the competition to
identify such genes is becoming increasingly
fierce.
2.5 Current state of
development work on
pharmaceutical products for
Alzheimer's disease
No infallible remedy has been developed for
Alzheimer's disease. Since therapeutic drugs for
Alzheimer's disease with higher efficacy could
produce large profits, research and development
aiming at introducing such a drug into the market
has been very actively conducted with the
involvement of many companies. On the other
hand, it is also important to develop prophylaxes,
because histopathological changes in the brains of
Alzheimer's disease patients have already become
irreversible at the time when clinical symptoms of
the disease appear.
The following paragraphs in this section briefly
introduce major drugs currently used in the
treatment of Alzheimer's disease, or are under
research and development, as well as the current
state of major studies targeting the development
of therapeutic drugs.
2.5.1  Drugs for Alzheimer's disease
Currently, not many drugs are used in the
treatment of Alzheimer's disease, and the drugs
prescribed to patients with the disease are mostly
represented by antipsychotic agents, anti-
depressants, antianxiety agents, hypnotic drugs,
etc., targeting symptoms associated with the
disease including depression.
Donepezil hydrochloride (trade name: Aricept) is
the only drug so far to have gained marketing
approval in Japan for use in improving symptoms
specifically seen in patients with Alzheimer's
disease (approved in November 1999). It has been
shown that acetylcholine, a neurotransmitter
associated with memory, etc., decreases in the
brains of patients with Alzheimer's disease.
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Figure 3: Normal tau protein and abnormal tau protein
Source: Authors' compilation by making reference to the materials provided by Professor Iwatsubo.
Donepezil hydrochloride is an acetylcholinesterase
inhibitor that interferes with the degradation of
acetylcholine in the synapse to increase available
acetylcholine. The drug can delay the progression
of early-stage Alzheimer's disease to a certain
degree.
2.5.2  Studies on therapies focusing on the
accumulation of Aß
Aβ is thought to be closely involved in the
development of Alzheimer's disease. At present,
studies on the following five therapies aiming to
inhibit the accumulation of Aβ are in progress:
Firstly, reports have been made on studies on
"vaccine therapy" (administration of a segment of
the Aβ peptide):Alzheimer's disease model mice in
which APP is overexpressed were immunized with
Aβ, leading to the generation of antibodies, which
prevented the accumulation of Aβ within the
mouse brain and even markedly decreased
existing Aβ deposits, known as plaques. Secondly,
results of studies on "antibody therapy" (passive
immunization with antibody administration
specific to the Aβ peptide)  have also been
reported. Studies on these two therapies have
advanced rapidly and clinical studies on these
therapies are underway in the United States.
However, concerning the vaccine therapy, new
problems to be tackled have arisen recently,
including adverse reactions of the central nervous
system.
Thirdly, several nonsteroidal anti-inflammatory
drugs (NSAIDs) including indomethacin and
ibuprofen have been reported to exert effects in
the treatment of Alzheimer's disease. In addition,
in studies using Alzheimer's disease model mice
orally given NSAIDs and experiments using
cultured cells, generation and accumulation of Aβ
have been reported to decrease. While the
mechanism of inhibition of Aβ generation and
accumulation by NSAIDs are being clarified,
further investigation is required.
Fourthly, studies on gamma-secretase inhibitors
specifically targeting gamma secretase have been
conducted. In experiments using Alzheimer's
disease model mice, gamma secretase inhibitors
have been reported to be effective in, for example,
inhibiting the accumulation of Aβ. It is expected
that gamma secretase inhibitors can be a class of
the next-generation drugs, which are effective in
preventing the onset and inhibiting the
progression of Alzheimer's disease, and clinical
studies on some gamma secretase inhibitors have
started in the United States. However, gamma
secretase has been found to have substrates other
than APP, and there is a possibility that gamma
secretase-mediated reaction with APP might be
disturbed by such substrates, so there remain
problems to be resolved before gamma secretase
inhibitors are brought to the market as therapeutic
drugs for Alzheimer's disease.
Lastly, studies focusing on beta secretase have
been actively conducted recently. It has been
reported that knockout mice missing genes for
beta-secretase do not seem to exhibit any
abnormality in general, and that accumulation of
Aβ is not seen in the brains of such mice. Many
pharmaceutical companies are reportedly
competing fiercely to develop gamma secretase
inhibitors as therapeutic drugs for Alzheimer's
disease, but most of the results of studies they
conducted have not been published. Introduction
of gamma secretase inhibitors to the market
requires further advances in research.
2.5.3  Studies on biochemical markers
Studies have also been performed on specific
biochemical markers of Alzheimer's disease. As in
the cases of other diseases whose severity or risk
can be known from the results of blood tests
including the quantitative evaluation of blood
sugar and serum cholesterol, risk or stage of
Alzheimer's disease might be known from the
results of examination on specific biochemical
markers, which may possibly lead to the
prevention or delay of onset of the disease
through adequate prophylactic treatment.
Currently, studies are being pursued on the
relationship between the level of Aβ or excessively
phosphorylated tau protein in cerebrospinal fluid
taken from Alzheimer's disease patients and the
stage of Alzheimer's disease. However, many
problems should be addressed before the
utilization of such relationship for diagnosing the
disease in that invasiveness of cerebrospinal fluid
sampling is so high and that utilization of the
levels of Aβ and excessively phosphorylated tau
protein require data sampling not only from
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patients with the disease but also from people
without the disease. Up to this time, no specific
molecular markers have been found other than
Aβ42 and hyperphosphorylated  tau protein in
cerebrospinal fluid. Under such current realities,
many problems have to be tackled before the
preclinical diagnosis of Alzheimer's disease
becomes utilizable in actual clinical practice,
including the exploration of new molecular
markers, determination of reference values and the
development of less invasive diagnostic
techniques.
2.5.4  Development of new materials for
diagnostic imaging with PET
With regard to measures to investigate cerebral
histopathological changes in living patients,
development work is proceeding to develop
techniques for detecting the distribution and the
amount of Aβ in senile plaques and neurofibrillary
tangles in the brain with the use of PET (positron
emission tomography). The first isotope probe for
use in such PET examination has been reportedly
developed. Currently, fierce competition is being
intensified to develop better isotope probes,
which can pass through the blood-brain barrier
and are specifically bound to Aβ for the intended
time with unbound probes going out of the brain
rapidly. The PET examination using such isotope
probes will serve as a very useful technique in the
diagnosis of MCI (mild cognitive impairment)
discussed in the following section as well as in
future preclinical diagnosis of Alzheimer's disease.
2.5.5  Methods for diagnosing very early dementia
Also under development are methods for
diagnosing mild cognitive impairment (MCI: a
condition characterized by mild recent memory
loss without dementia or significant impairment of
other cognitive functions), which is regarded as
very early dementia but not clinically diagnosed as
dementia. According to a report on Alzheimer's
disease published in 1999 by the U.S. National
Institute of Health, an epidemiological survey of a
community cohort revealed that 40% of people
who had been given the diagnosis of MCI in
accordance with certain diagnostic criteria,
developed Alzheimer's disease within 3 years of
the diagnosis. In Japan, efforts are underway to
make draft diagnostic criteria for MCI highly
adaptable to Japanese people.
2.6 Strategies for
promoting research on
Alzheimer's disease in Japan
In March 1997, the Bioscience Section of the
Scientific Council, Ministry of Education, Culture,
Sports, Science and Technology submitted a report
titled "Promotion of Brain Research at Universities,
etc." and then, in May 1997, the Brain Science
Committee, Life Science Section, Council for
Science and Technology submitted a report titled
"Long-term Prospects of Brain Research."  In the
latter report, three areas of brain research were set
up including "Understanding the Brain,"
"Protecting the Brain" and "Creating the Brain."  In
addition, a strategic timetable was developed in
the latter report, targeting the suppression of
various diseases including Alzheimer's disease,
which was planned to be overcome within 15
years (as of 1997). Moreover, also in the Second
Science and Technology Basic Plan, elucidation of
the mechanism of brain aging and suppression of
nervous system diseases were adopted as
challenges to be addressed.
Based on the above-mentioned policies, research
in the field of brain science in Japan as a whole
has been greatly encouraged and studies on
dementia have also been promoted. In 1997, the
"Brain Science Institute (BSI)" was established
under the Institute of Physical and Chemical
Research as the engine that will drive brain
science research. At the BSI, the Laboratory for
Alzheimer's disease and the Laboratory for
Proteolytic Neuroscience of the Aging in
Psychiatric Research Group take charge of studies
on Alzheimer's disease and are investigating the
mechanisms of the occurrence of neurofibrillary
degeneration, nerve cell death, degradation of Aβ,
etc.
Publicly funded studies aiming to address
challenges to be dealt with for the suppression of
Alzheimer's disease, which were invited from the
public, have also been performed. Under the
Scientific Research Subsidy System, various
challenges to be addressed have been chosen as
themes of fundamental studies (in the fields of
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pathology, pharmacology, pharmaceutical
sciences, medicine, neuroscience, etc.), which are
to be promoted with public monetary support. In
addition, studies on dementia (including those on
Alzheimer's disease) have been conducted as
studies in the fields with high priority or in special
fields almost in succession since 1989.
Furthermore, as part of the Millennium Project,
"Studies in Special Fields C" has been set since
2000, and "Studies in Frontier Brain Science"
including studies on Alzheimer's disease have been
started to deal with one of the themes in the
Studies in Special Fields C.
Under the Funds for the Coordination of
Advancement of Technology System and under the
Core Research for Evolutional Science and
Technology (CREST) system set up by the Japan
Science and Technology Corporation, brain-related
themes have been selected for study to be publicly
funded every year from 1997 and from 1995 to
2000, respectively. Under these systems, studies
on Alzheimer's disease have been performed from
1996 to 2001.
In addition, also under the Scientific Research
Subsidiary System established by the Ministry of
Health, Labor and Welfare, studies on Alzheimer's
disease have been conducted.
According to the Human Frontier Science Program
(HFSP), monetary support has been provided to
studies on brain functions within the international
framework for the promotion of such studies.
Within the framework, basic research on dementia
including Alzheimer's dementia has also been
performed.
2.7 Conclusion
— Challenges to be addressed
through research on Alzheimer's 
disease —
Now that several genes associated with the onset
of Alzheimer's disease have been identified,
postgenome research on the disease will assume
more significance from this day forward. While
elucidation of the pathways leading to abnormal
protein accumulation is one of the important
challenges to be addressed in future studies, as
discussed in section 2.4, it is also significant to
analyze conformational structures of proteins or
complexes of proteins as functional units involved
in such pathways. In addition, studies on SNPs
(single nucleotide polymorphisms: a kind of
genetic polymorphism) associated with sporadic
(non-familial) Alzheimer's disease will become
more important from now on. In order to
promote such postgenome research, it is crucial to
have collaboration among specialists in various
fields including medicine, pharmaceutical sciences
and science.
Since Alzheimer's disease will constitute a bigger
concern with the increasing graying of Japanese
society, studies on the disease need to be
conducted more widely and deeply. In addition,
since studies on Alzheimer's disease are not pure
academic research but a sort of purpose-oriented
research, it is desired that researchers who are not
clinicians as well as experts in government,
academia and industry should participate in such
studies. Some people point out that Japan has no
established system to introduce researchers in
such fields as science, pharmaceutical sciences
and agriculture into research on diseases.
Alzheimer's disease occurs "only in the highly
developed human brains" and it is essential, in
every study conducted by experts in the
government, academia and industry, to use
biological samples (tissue samples, DNA samples)
taken from patients with the disease. Therefore, it
is important to construct systems for appropriate
collection and accessible supply of samples for
research taken from Alzheimer's disease patients.
Until now, even universities with attached
hospitals have faced difficulty in obtaining
samples for research from affected patients, and
most institutes for research on Alzheimer's disease
have purchased from overseas brain banks. In
order to further facilitate studies on Alzheimer's
disease from now on, it is required that brain
banks be established in Japan to collect biological
samples (samples of brain tissue, cerebrospinal
fluid, blood, etc.) from a large number of patients
with Alzheimer's disease and supply those samples
to researchers with due consideration for the
significance of informed consent, protection of
private information as well as ethical implications
of such sample collection and distribution.
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